ATE347599T1 - Tuberkulose impfstoff - Google Patents

Tuberkulose impfstoff

Info

Publication number
ATE347599T1
ATE347599T1 AT98947427T AT98947427T ATE347599T1 AT E347599 T1 ATE347599 T1 AT E347599T1 AT 98947427 T AT98947427 T AT 98947427T AT 98947427 T AT98947427 T AT 98947427T AT E347599 T1 ATE347599 T1 AT E347599T1
Authority
AT
Austria
Prior art keywords
nucleic acid
acid molecules
present
tuberculosis vaccine
novel recombinant
Prior art date
Application number
AT98947427T
Other languages
English (en)
Inventor
Stefan H E Kaufmann
Juergen Hess
Original Assignee
Max Planck Gesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Max Planck Gesellschaft filed Critical Max Planck Gesellschaft
Application granted granted Critical
Publication of ATE347599T1 publication Critical patent/ATE347599T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
AT98947427T 1997-08-22 1998-08-12 Tuberkulose impfstoff ATE347599T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP97114614A EP0902086A1 (de) 1997-08-22 1997-08-22 Tuberkolose Impfstoff

Publications (1)

Publication Number Publication Date
ATE347599T1 true ATE347599T1 (de) 2006-12-15

Family

ID=8227261

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98947427T ATE347599T1 (de) 1997-08-22 1998-08-12 Tuberkulose impfstoff

Country Status (13)

Country Link
US (1) US6673353B1 (de)
EP (2) EP0902086A1 (de)
JP (1) JP4255209B2 (de)
AT (1) ATE347599T1 (de)
AU (1) AU9435098A (de)
CA (1) CA2301879C (de)
CY (1) CY1106350T1 (de)
DE (1) DE69836588T2 (de)
DK (1) DK1007686T3 (de)
ES (1) ES2274580T3 (de)
PT (1) PT1007686E (de)
SI (1) SI1007686T1 (de)
WO (1) WO1999010496A1 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6051237A (en) 1994-11-08 2000-04-18 The Trustees Of The University Of Pennsylvania Specific immunotherapy of cancer using a live recombinant bacterial vaccine vector
US7820180B2 (en) 2004-09-24 2010-10-26 The Trustees Of The University Of Pennsylvania Listeria-based and LLO-based vaccines
US8114414B2 (en) 1994-11-08 2012-02-14 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of cervical cancer
US8956621B2 (en) 1994-11-08 2015-02-17 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of cervical dysplasia
US7794729B2 (en) 1994-11-08 2010-09-14 The Trustees Of The University Of Pennsylvania Methods and compositions for immunotherapy of cancer
US7662396B2 (en) 2001-03-26 2010-02-16 The Trustees Of The University Of Pennsylvania Compositions and methods for enhancing the immunogenicity of antigens
US8791237B2 (en) 1994-11-08 2014-07-29 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of non-hodgkins lymphoma
EP1144447B1 (de) 1998-11-04 2009-10-14 Isis Innovation Limited Tuberkulose diagnose test
GB0006693D0 (en) * 2000-03-20 2000-05-10 Glaxo Group Ltd Vaccine
US9012141B2 (en) 2000-03-27 2015-04-21 Advaxis, Inc. Compositions and methods comprising KLK3 of FOLH1 antigen
US6855320B2 (en) 2000-03-29 2005-02-15 The Trustees Of The University Of Pennsylvania Fusion of non-hemolytic, truncated form of listeriolysin O to antigens to enhance immunogenicity
AU2001255196A1 (en) 2000-03-29 2001-10-08 The Trustees Of The University Of Pennsylvania Compositions and methods for enhancing immunogenicity of antigens
US8771702B2 (en) 2001-03-26 2014-07-08 The Trustees Of The University Of Pennsylvania Non-hemolytic LLO fusion proteins and methods of utilizing same
US7700344B2 (en) 2001-03-26 2010-04-20 The Trustees Of The University Of Pennsylvania Compositions and methods for enhancing the immunogenicity of antigens
CA2515369C (en) * 2003-02-06 2015-03-31 Cerus Corporation Listeria attenuated for entry into non-phagocytic cells, vaccines comprising the listeria, and methods of use thereof
BRPI0409789B8 (pt) * 2003-04-23 2021-05-25 Max Planck Gesellschaft célula bacteriana, seus processos de preparação e seu uso, composição, e processo para a preparação de uma vacina viva
EP1649869A1 (de) * 2004-10-21 2006-04-26 Vakzine Projekt Management GmbH Kombination von rekombinanten Mycobakterien und einem biologisch aktiven Agent als Vakzine
AU2005338353B2 (en) * 2004-12-01 2011-04-14 Aeras Global Tb Vaccine Foundation Recombinant BCG strains with enhanced ability to escape the endosome
ES2657168T3 (es) 2006-08-15 2018-03-01 The Trustees Of The University Of Pennsylvania Composiciones que comprenden HMW-MAA y fragmentos de este para el tratamiento del cáncer
US8268326B2 (en) 2006-08-15 2012-09-18 The Trustees Of The University Of Pennsylvania Compositions comprising HMW-MAA and fragments thereof, and methods of use thereof
EP2288379A4 (de) 2008-05-19 2012-08-08 Advaxis Doppeltes freisetzungssystem für heterologe antigene
US9017660B2 (en) 2009-11-11 2015-04-28 Advaxis, Inc. Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors
US9650639B2 (en) 2008-05-19 2017-05-16 Advaxis, Inc. Dual delivery system for heterologous antigens
DK2403935T3 (en) 2009-03-04 2017-09-11 Univ Pennsylvania COMPOSITIONS CONTAINING ANGIOGENIC FACTORS AND METHODS OF USE THEREOF
US10016617B2 (en) 2009-11-11 2018-07-10 The Trustees Of The University Of Pennsylvania Combination immuno therapy and radiotherapy for the treatment of Her-2-positive cancers
HUE048774T2 (hu) * 2010-09-20 2020-08-28 Vakzine Projekt Man Gmbh Rekombináns Mycobacterium vakcinaként embereken történõ alkalmazásra
JP5981436B2 (ja) 2010-10-01 2016-08-31 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 寄生的に感染している対象におけるワクチン不応答性を反転させるためのリステリアワクチンベクターの使用
EA029833B9 (ru) 2010-12-21 2018-06-29 Макс-Планк-Гезельшафт Цур Фёрдерунг Дер Виссеншафтен Е.В. Способ определения эффективности против микобактериальных инфекций рекомбинантной живой вакцины и варианты набора реагентов для его осуществления
BR112013015882B8 (pt) * 2010-12-21 2021-01-05 Max Planck Gesellschaft célula recombinante de mycobacterium bovis (m. bovis) do bacillus calmette-guérin (bcg) da cepa danish subtipo prague e uso da mesma
CA2829960A1 (en) 2011-03-11 2012-09-20 John Rothman Listeria-based adjuvants
BR102012003790A2 (pt) 2012-02-17 2014-04-22 Fundacao Butantan Cepa de mycobacterium recombinante, composição imunogênica e uso
BR112014022662A2 (pt) 2012-03-12 2017-10-03 Advaxis Inc Inibição da função de célula supressora seguindo tratamento de vacina de listeria
EP2834356A4 (de) * 2012-04-02 2015-09-02 Univ Arizona Rekombinantes bakterium zur induktion einer zellulären immunantwort

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5504005A (en) * 1987-03-02 1996-04-02 Albert Einstein College Of Medicine Of Yeshiva University Recombinant mycobacterial vaccine

Also Published As

Publication number Publication date
ES2274580T3 (es) 2007-05-16
PT1007686E (pt) 2007-03-30
CA2301879C (en) 2014-02-04
US6673353B1 (en) 2004-01-06
EP0902086A1 (de) 1999-03-17
DE69836588D1 (de) 2007-01-18
WO1999010496A1 (en) 1999-03-04
CY1106350T1 (el) 2011-10-12
CA2301879A1 (en) 1999-03-04
JP4255209B2 (ja) 2009-04-15
EP1007686B1 (de) 2006-12-06
DE69836588T2 (de) 2007-04-05
AU9435098A (en) 1999-03-16
JP2001514000A (ja) 2001-09-11
DK1007686T3 (da) 2007-04-10
SI1007686T1 (sl) 2007-04-30
EP1007686A1 (de) 2000-06-14

Similar Documents

Publication Publication Date Title
DK1007686T3 (da) Tuberkulosevaccine
HK1091217A1 (en) Tuberculosis vaccine with improved efficacy
BRPI9912663B1 (pt) vacina contra cáncer e polipeptìdeo.
DE69131580T2 (de) GDF-1 und UOG1 Proteine
DE69734882D1 (de) Dna immunisierung gegen chlamydia infektion
DK1025211T3 (da) Hyaluronansyntasegen og anvendelser deraf
ATE429504T1 (de) Proteinexpressionsvektor und benutzung desselbigen
DE69930955D1 (de) Polypeptide mit lysophospholipaseaktivität und nukleinesäuren die sie kodieren
DK251890D0 (da) Polypeptid og dets anvendelse samt ekspressionssystem til dets eksprimering
AU1013701A (en) Modified gp100 and uses thereof
DE69230671D1 (de) Impfstoffe gegen actinobacillus pleuropneumonie
GB9922361D0 (en) Generating an immune response to an antigen
NO983946D0 (no) Parapoksyviruser inneholdende fremmed DNA, fremstilling og anvendelse derav i vaksiner
DK0754229T3 (da) Afamin: et humant serum albumin-lignende protein
FI20070041A (fi) Parannettu rokote Flavivirusinfektioiden vastaiseen immuunisointiin
ATE346931T1 (de) Clostridium perfringens impfstoff
BR0011469A (pt) Gm-csf equina
CY2008005I1 (el) Εμβολιο κατα της παρωτιτιδας που περιεχει στελεχος ιου jeryl-lynn
CA2148369A1 (en) Actinobacillus pleuropneumoniae outer membrane lipoprotein a and uses thereof
BR0013574A (pt) Antìgeno vacina de moraxella
ATE236979T1 (de) Leishmania hauptprotein, dafür kodierende nukleinsaüre und verwendungen davon
BR0016740A (pt) Antìgenos de esporozoìto de cryptosporidium
NO871737D0 (no) Rekombinant virus, polypeptid samt dna molekyl med kodingssekvens for dette polypeptid.
DK52893D0 (da) Polypeptides, dna coding for the polypeptides, and uses thereof

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1007686

Country of ref document: EP